Trastuzumab Terminated Phase 2 Trials for Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01220128Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer